Arm Holdings plc - American Depositary Shares (ARM)

Invivyd (NASDAQ:IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration. The compan

Ford's commercial division and dealership network contrast sharply with Stellantis's lower debt, but both posted massive losses in 2025.

One specializes in AI connectivity with explosive growth but heavy customer concentration, while the other licenses foundational chip architecture with stable margins.

One is growing faster but trading at a higher valuation while sacrificing near-term profits to capture market share. The other is growing steadily, generating substantial free cash flow, and trading at a more modest premium.

Meta's new Muse agent helped lift CPU stocks, including AMD.

Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit

What Happened? Shares of semiconductor manufacturer Vishay Intertechnology (NYSE:VSH) jumped 11.1% in the afternoon session after the company released four n...

Two of these stocks are risky bets.

One designs the chips, while the other manufactures the machines that build them. But their valuations tell a starkly different story.

Arm compounds reliably across billions of devices. Credo is posting near-triple-digit growth in AI data center connectivity. The growth gap is significant, and so is the valuation gap.

Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or AL

(BPT) - Erik Lofstrand never expected a routine physical to change his life. But when he was diagnosed with Type 2 diabetes, Erik suddenly found himself navigating a life-changing condition.

Ultimately, it is difficult to argue with a 251,000% lifetime return.

AMD is growing fast as the primary alternative to Nvidia in AI chips, with data center sales more than doubling year over year. Arm earns royalties across billions of devices and is finding new momentum in data centers, but its growth is more measured.

As is so often the case, the best opportunities are often hiding behind the headline name.

Oracle's AI business is booming. The question is whether its cash flow can catch up with its spending.

The ZET SCALE sales agreement removes one of the biggest obstacles to Tesla heavy truck demand.

Nebius management could decide to split the stock following a big jump in the company's stock price this year.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor exec...

Tesla's Semi truck has entered volume production at a new Nevada factory after nine years, with record diesel prices boosting its cost case, though analysts say it won't significantly move TSLA stock.

NVIDIA's new AI safety platform could boost demand for inference infrastructure, with analyst Luke Lango pointing to Marvell, Arm Holdings and Lumentum as key beneficiaries.

This rare-earth investment is like a diamond in the rough.

Arm's licensing model commands a steep valuation premium, while Marvell is growing faster but depends heavily on a small group of large customers.

Longer-term bond yields are at some of the highest levels seen since right before the Great Recession in 2007.